A closer reading
Why one compound has two names
You will see citicoline and CDP-choline used in the same paragraph, sometimes in the same sentence. They are not two related substances or two versions of one substance. They are two labels for the same molecule. "Citicoline" is the name used most often on supplement bottles and in general discussion. "CDP-choline," short for cytidine diphosphate-choline, is the name you are more likely to see in study titles and chemistry writing.
This matters for a practical reason. If you search a research database for only one of the two names, you will miss part of the record. A reader checking a supplement label against a published trial should know that a trial of "CDP-choline" is a trial of the same compound on the shelf. The CDP-choline and citicoline page covers the naming question on its own. Branded forms add a third layer: Cognizin is a brand of this same compound, not a different molecule. A brand name on a label does not change what the evidence says about the compound itself.
What the compound does in the body, and what that does not prove
After you swallow citicoline, the body splits it into two parts: choline and cytidine. The cytidine is then converted toward uridine. Choline and uridine are both raw materials the body uses when it builds phospholipids, the fatty molecules that make up cell membranes. Because brain cells are rich in membranes, researchers have proposed that supplying these building blocks could support membrane repair and maintenance in the brain.
That is a plausible mechanism, and laboratory evidence supports the membrane-building part of the story. It is important to be exact about the limits. Much of the "neuroprotection" language around citicoline comes from preclinical work: cell cultures and animal models. A compound that protects neurons in a dish, or in a rat given an experimental injury, does not automatically protect neurons in a person. The step from mechanism to clinical benefit is where many promising compounds fail, and the clinical record for citicoline reflects that gap. The largest human trials, described below, did not confirm the benefits the laboratory work suggested.
So when you read that citicoline "supports brain cell membranes," treat that as a statement about biology, not a statement about health outcomes. Mechanism is a reason researchers studied the compound. It is not a result.
What the large trials actually found
The most important thing this site can tell you is that the biggest, best-run trials of citicoline were negative. Any honest account of the compound starts there.
The ICTUS trial, published in The Lancet in 2012 by Dávalos and colleagues, enrolled about 2,300 people with acute stroke. It is the largest citicoline trial ever run. It found no improvement in 90-day recovery compared with placebo. This result matters even more because earlier meta-analyses, which pooled smaller stroke trials, had suggested a benefit. The largest trial did not confirm those suggestions. When a small body of evidence points one way and a large rigorous trial points the other, the large trial carries more weight.
The COBRIT trial, published in JAMA in 2012 by Zafonte and colleagues, tested citicoline after traumatic brain injury. It did not improve functional or cognitive outcomes compared with placebo. Again: a serious trial, a clear question, and a negative answer.
These results are why this site does not say citicoline treats or prevents stroke or brain injury, and why you should treat any source that says otherwise with caution. If you ever see sudden facial droop, arm weakness, or speech difficulty, that can be a stroke. Call 911 immediately. No supplement is a substitute for emergency care, and minutes matter in stroke treatment.
Where the evidence is weaker but more positive
Some areas of the citicoline literature show positive signals, but on a smaller and less certain footing than the trials above.
For chronic cerebrovascular cognitive decline, a Cochrane review by Fioravanti and Yanagi found modest short-term benefit on memory and behaviour. The review's own caution is part of the finding: the included trials were short and of low quality, so the estimate could shrink or disappear with better studies. For mild vascular cognitive impairment, the IDEALE study by Cotroneo and colleagues reported an association between citicoline use and stable scores over time, while an untreated group declined. This was observational, not randomized, which means people who took citicoline may have differed from those who did not in ways the study could not fully account for. Association is not proof of effect. The memory evidence page goes deeper on this area.
For glaucoma, small trials from the Parisi and Rossetti groups reported changes in electrophysiological measures when citicoline was used alongside standard care. Whether those changes translate into slowing actual vision loss is not established. The glaucoma evidence page explains why that distinction matters for a condition where the outcome that counts is keeping your sight.
For healthy adults, a 2012 study by McGlade and colleagues in women found better scores on attention tests at 250 mg and 500 mg doses. A separate McGlade study in adolescent males found gains in attention and psychomotor speed. Both were small and funded by the maker of Cognizin, a citicoline brand. Industry funding does not make results false, but it is a reason to want independent replication before drawing strong conclusions.
For ADHD, the honest summary is short: there are no adequate trials, and there is no good evidence citicoline treats ADHD. The ADHD evidence page says this plainly, because people searching that topic deserve a direct answer rather than hopeful language.
How to read citicoline claims in the wild
Most citicoline content online is written to sell something. That does not make every claim wrong, but it changes how you should read it. A few habits help.
First, check which name and which population a claim is about. A study in people with vascular cognitive impairment says nothing direct about a healthy 30-year-old, and a study of a branded form is still a study of citicoline, not proof the brand outperforms the plain compound.
Second, look for the big trials. A seller citing early stroke meta-analyses while omitting ICTUS is showing you half the record. Negative results are results.
Third, separate mechanism from outcome. "Supports membrane phospholipid synthesis" is a statement about chemistry. It is not evidence that memory, attention, or vision improves.
Fourth, check who paid. Industry-funded studies are common in supplement research and deserve extra weight placed on replication, not dismissal, but also not blind trust.
Safety in brief, and questions worth asking
Across trials, citicoline has been generally well tolerated at doses from 250 to 2,000 mg per day. The side effects reported most often are mild: stomach upset, headache, and insomnia. Data in pregnancy and breastfeeding are lacking, so this site cannot say it is safe in those situations. One interaction deserves attention: citicoline may enhance the effects of levodopa, so people with Parkinson's disease should involve their neurologist before trying it. The side effects page and the dosage page cover these topics in more depth, and the questions for your doctor page helps you prepare for that conversation.
"Well tolerated in trials" is not the same as "proven safe for everyone forever." Trials are shorter than real life and exclude many people. That is a reason to involve your doctor, not a reason for alarm.
Where to go next
This page is the starting point, not the whole map. The evidence hub walks through citicoline condition by condition, with negative trials stated as clearly as positive ones. If you are comparing choline sources, the citicoline vs alpha-GPC page puts the two side by side. If you decide, with your doctor, that you want to try a supplement, the choosing a supplement page covers quality and labeling questions. The about page explains who runs this site and how pages are written, and the reference blog collects shorter explainers as the literature develops.
